Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement

Sponsor

University of Bordeaux (Other)

Overall Status

Completed

CT.gov ID

NCT06118125

Collaborator

(none)

376

Enrollment

Location

Actual Duration (Months)

9.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Objective: the pre-hospital management of cancers is little known in General Medicine. The first lockdown related to the COVID-19 pandemic led to the closure of health facilities. Investigators were interested in the diagnosis and care pathway of digestive cancers in post-confinement in General Medicine in Nouvelle-Aquitaine.

Condition or Disease	Intervention/Treatment	Phase
Neoplasms, Colorectal General Practitioner Pandemic, COVID-19 Neoplasm, Liver Neoplasms Pancreatic Diagnosis Advanced Cancer

Detailed Description

Method: patient records discussed in Digestive Oncology CPR of Bordeaux University Hospital for the first time from June 1 to August 31, 2020 and over the same period in 2019 were included. A questionnaire on the dates of the first symptoms, first consultation with the general practitioner, imaging examination and access to the specialist was sent to the general practitioner. The primary outcome was time from onset to date of first MDT.

Study Design

Study Type:

Observational

Actual Enrollment :

376 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Delay to Diagnosis and Management in Digestive Cancerology by the General Practitioner Within the City-hospital Network in the Context of Confinement Related to the Covid-19 Pandemic

Actual Study Start Date :

Jun 1, 2019

Actual Primary Completion Date :

Sep 1, 2022

Actual Study Completion Date :

Sep 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
2019 patients diagnosed in 2019
2020 patients diagnosed in 2020

Outcome Measures

Primary Outcome Measures

time from date of first symptoms of cancer to the date of first MDT [DAYS]
time from date of first symptoms of cancer to the date of first MDT

Secondary Outcome Measures

time from date of first symptoms to date of first consultation with a general practitioner, [DAYS]
time from date of first symptoms to date of first consultation with a general practitioner,
time from date of first symptoms to first imaging or specific examination, [DAYS]
difficulties in referral to imaging,
time from date of first symptoms to consultation with a specialist, [DAYS]
difficulties in referral to a specialist,
stage of pathology by type of cancer, [at inclusion]
stage of pathology by type of cancer according to TNM classification (tumor, node, metastatic status)
frequency of different types of cancer, [at inclusion]
PERCENTAGE of each type of cancers in this study
overall survival. [MONTHS, time from from date of first symptoms to date of death]
overall survival.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

residing in New Aquitaine and
whose general practitioner practiced in New Aquitaine
malignant tumors of the esophagus, stomach, small intestine, colon, recto-sigmoid junction, rectum, anus and anal canal, liver and intrahepatic bile ducts, extrahepatic bile ducts, gallbladder and pancreas.
to have had at least one consultation or hospitalization in the digestive pole of the Bordeaux University Hospital within 6 months after the MDT.

Exclusion Criteria:

Patients under 18 years of age,
who had already had a MDT for this cancer,
whose date of first MDT was outside the inclusion dates,
whose new cancer was a digestive metastasis of a primary of another location,
who did not have French health insurance

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Blanc-Bisson Christele	Bordeaux		France	33076

Sponsors and Collaborators

University of Bordeaux

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Blanc-Bisson Christele, Doctor, University of Bordeaux

ClinicalTrials.gov Identifier:

NCT06118125

Other Study ID Numbers:

2023-A02271-44

First Posted:

Nov 7, 2023

Last Update Posted:

Nov 7, 2023

Last Verified:

Nov 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Blanc-Bisson Christele, Doctor, University of Bordeaux

digestive cancer, covid

Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 7, 2023